Cancer diagnostics News and Research

RSS

MIRACLE project to develop lab-on-chip system for diagnosing cancer

Today, at the Engineering in Medicine and Biology Conference in Buenos Aires (Argentina), imec and its project partners announce the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells in blood.

2 Sep 2010

Leon-Berard Cancer Center to install CyberKnife VSI System

Accuray Incorporated, a global leader in the field of radiosurgery, today announced that the first CyberKnife VSI System to be installed in Europe was placed at the Leon-Berard Cancer Multidisciplinary Center in Lyon, France. The CyberKnife VSI System is the newest addition to the CyberKnife product family.

2 Sep 2010

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Bio-Reference Laboratories, Inc. (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $121,719, the best ever quarter in terms of revenues in corporate history and an increase of 25% over the $97,424 recorded in the third quarter, fiscal year 2009.

26 Aug 2010

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.

26 Aug 2010

PEM scanners demonstrate improved specificity with high sensitivity in breast cancer diagnosis: Study

In a recent study presented at the American Association of Physicists in Medicine (AAPM) 52nd Annual Meeting, researchers at the University of Washington showed that 18FDG dose for Positron Emission Mammography (PEM) may be reduced by as much as 70% without altering image quality.

24 Aug 2010

Early palliative care treatment for lung cancer can help patients live longer: Research

Introducing palliative care at an early stage of treatment for advanced lung cancer could help patients to live for longer, as well as improving their mood and quality of life.

23 Aug 2010

Study finds rectal cancer rates are increasing among young individuals

A new analysis has found that while colon cancer rates have remained steady over the past several decades among people under the age of 40, rectal cancer rates are increasing in this population across races and in both sexes.

23 Aug 2010

mBeach Software issues stockholder update for skin cancer diagnostic solutions

mBeach Software Inc. today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

21 Aug 2010

Palliative care prolongs metastatic lung cancer patient’s life: Study

A precedent-setting study published in the New England Journal of Medicine on Thursday, August 19 demonstrates definitively that early referrals to palliative care prolongs life for patients living with metastatic lung cancer.

21 Aug 2010

Research finds increased diagnostic activity among men with family history of prostate cancer

The brothers of men with prostate cancer are at an increased risk of prostate cancer diagnosis because of increased diagnostic activity and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a study published online August 19 in The Journal of the National Cancer Institute.

20 Aug 2010

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Europe's most promising oncology biotechs and other key stakeholders will gather in Oslo, Norway, September 15-17 for the 2nd European Cancer Cluster Meeting (ECCP 2010). Co-hosted by the Oslo Cancer Cluster and the Cancer-Bio-Santé Cluster from Toulouse, the two-day meeting is a unique partnering opportunity for oncology biotech companies, business development and licensing executives from the pharmaceutical industry and investors, as well as innovative researchers and clinicians.

17 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

NAEDI aims to correct survival gap in cancer diagnosis

Cancer Research UK today reveals that as many as 11,000 deaths from cancer could be prevented annually if Great Britain raised its survival figures to match those of the best performing countries in Europe.Cancer Research UK and national cancer director, Professor Mike Richards, believe that the most important reasons for the survival gap include poor awareness of the symptoms of cancer, late presentation to a GP and, late onward referral to hospital.

6 Aug 2010

Agendia inaugurates new clinical genomics laboratory

Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.

4 Aug 2010

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.

4 Aug 2010

BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

BioCurex Inc. today announced that the International Society of Oncology and Biomarkers Congress Scientific Committee has accepted BioCurex's presentation on the RECAF blood test potential to monitor cancer recurrence and treatment. The meeting will be held Sept. 3-8, 2010 in Munich, Germany and is broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics.

30 Jul 2010

Clarient second-quarter net revenue increases 21% to $28.7 million

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the second quarter ended June 30, 2010. Second quarter 2010 net revenue was $28.7 million, a 21 percent increase over the $23.7 million net revenue in the 2009 second quarter and a sequential increase of nearly eight percent over the $26.6 million in the first quarter of 2010.

29 Jul 2010

Zetiq reports self declaration CE mark of conformity for cervical cancer diagnostic kit

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports that it has fulfilled the essential requirements towards issuing a self declaration CE mark of conformity for its diagnostic product for identification of cervical cancer in cytological specimens.

27 Jul 2010

Cancer diagnostics News and Research

MIRACLE project to develop lab-on-chip system for diagnosing cancer

Leon-Berard Cancer Center to install CyberKnife VSI System

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

PEM scanners demonstrate improved specificity with high sensitivity in breast cancer diagnosis: Study

Early palliative care treatment for lung cancer can help patients live longer: Research

Study finds rectal cancer rates are increasing among young individuals

mBeach Software issues stockholder update for skin cancer diagnostic solutions

Palliative care prolongs metastatic lung cancer patient’s life: Study

Research finds increased diagnostic activity among men with family history of prostate cancer

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

NAEDI aims to correct survival gap in cancer diagnosis

Agendia inaugurates new clinical genomics laboratory

WaferGen launches SmartChip System for discovery, validation of biomarkers

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

Clarient second-quarter net revenue increases 21% to $28.7 million

Zetiq reports self declaration CE mark of conformity for cervical cancer diagnostic kit

eBook: Liquid biopsy in cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News